EPM2A-DT: A Drug Target / Disease Biomarker (G100507557)

Target Name: EPM2A-DT

NCBI ID: G100507557

EPM2A-DT

Other Name(s): FBXO30-DT | EPM2A divergent transcript | EPM2A divergent transcript, transcript variant 1 | EPM2A-DT variant 1

EPM2A-DT: A Drug Target / Disease Biomarker

EPM2A-DT is a protein that is expressed in the brain and is known for its role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease. The EPM2A gene has been associated with the development of numerous neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

The EPM2A gene has four exons, which are the four different parts of the protein that are encoded by the gene. The first exon codes for the amino acid Asp, which is a key structural protein that is involved in many cellular processes. The second exon codes for the amino acid Asn, which is a non-structural protein that is involved in the regulation of gene expression. The third exon codes for the amino acid Asp, which is a key structural protein that is involved in many cellular processes. The fourth exon codes for the amino acid Asn, which is a non-structural protein that is involved in the regulation of gene expression.

EPM2A-DT is a transmembrane protein, which means that it spans the cell membrane and is located in the brain. It is thought to play a role in the regulation of the brain microenvironment, which includes the blood-brain barrier and the endothelial cells that line the brain blood vessels. This protein may be involved in the development and progression of neurodegenerative diseases by contributing to the regulation of the cells that are responsible for maintaining the health and function of the brain.

One of the most promising aspects of EPM2A-DT is its potential as a drug target. By targeting this protein with drugs, researchers may be able to reduce the risk of neurodegenerative diseases and improve treatment outcomes. This protein is also a good candidate for use as a biomarker, which could be used to monitor the effectiveness of drugs in patients with neurodegenerative diseases.

In conclusion, EPM2A-DT is a protein that is expressed in the brain and is known for its role in the development and progression of neurodegenerative diseases. Its structure and function have been studied extensively, and it is thought to play a role in the regulation of the brain microenvironment. As a drug target, EPM2A-DT has great potential for the treatment of neurodegenerative diseases, and as a biomarker, it could be used to monitor the effectiveness of drugs in patients with these conditions. Further research is needed to fully understand the role of EPM2A-DT in neurodegenerative diseases and to develop effective treatments.

Protein Name: EPM2A Divergent Transcript

The "EPM2A-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPM2A-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets